Open call for tenders
Non-Clinical Toxicology and safety assessment of a small molecule
Research and experimental development services · for Helmholtz-Zentrum für Infektionsforschung GmbH · Germany · published in German
What the buyer wants
The overall objective of the present project is to conduct a comprehensive nonclinical toxicology and safety assessment program for a small-molecule drug candidate. The program is intended to characterize the toxicological and safety pharmacology profile of the test item following intravenous infusion and to generate the nonclinical safety data required to support a first-in-human clinical trial and subsequent clinical development. The program shall be conducted in accordance with applicable regulatory requirements and guidelines and shall generate data and documentation suitable for regulatory submissions in the European Union and the United States. Particular attention shall be given to the assessment of renal safety, including the characterization of potential effects of both the test item and the vehicle on renal function and renal toxicity. In addition, the program includes the toxicological assessment of the test item following dermal administration to support the potential clinical evaluation of a semisolid formulation for topical administration. The dermal program is behind a Go/No-Go decision.
Companies that won similar tenders
Companies that won public tenders in the same category (Research and experimental development services) since 2024, according to EU award notices. Likely competitors, or partners for a joint offer.
- Quantasoft · Czechia1 win · last 24 Aug 2026
- STYRAX · Czechia1 win · last 24 Aug 2026
- Cilcare · France1 win · last 17 Dec 2025
- Teknologian tutkimuskeskus VTT · Finland1 win · last 24 Nov 2025
- Srini · Estonia1 win · last 22 Jul 2025
- ASITIS · Czechia1 win · last 24 Jun 2025
- SeqVision · Lithuania1 win · last 3 Jun 2025
- Novalix · France1 win · last 17 Apr 2025
- FAGOFARMA · Czechia1 win · last 2 Sep 2024
- EGU · Czechia1 win · last 29 Mar 2024